PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri Sells 30,432 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri sold 30,432 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $62.97, for a total value of $1,916,303.04. Following the completion of the transaction, the executive vice president now directly owns 62,472 shares in the company, valued at approximately $3,933,861.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alaleh Nouri also recently made the following trade(s):

• On Monday, March 18th, Alaleh Nouri sold 441 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $48.83, for a total transaction of $21,534.03.
• On Wednesday, March 6th, Alaleh Nouri sold 2,749 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $46.67, for a total transaction of $128,295.83.
• On Friday, February 9th, Alaleh Nouri sold 14,694 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $49.97, for a total transaction of $734,259.18.
• On Wednesday, February 7th, Alaleh Nouri sold 5,306 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $49.95, for a total value of $265,034.70.

PROCEPT BioRobotics Stock Up 4.2 %

Shares of PRCT stock opened at $64.31 on Friday. PROCEPT BioRobotics Co. has a fifty-two week low of $24.83 and a fifty-two week high of $64.89. The firm has a market capitalization of $3.31 billion, a PE ratio of -30.33 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.77 and a current ratio of 7.63. The stock’s 50-day simple moving average is $50.25 and its 200-day simple moving average is $43.72.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04. The firm had revenue of $44.50 million during the quarter, compared to analysts’ expectations of $41.58 million. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 42.13%. The firm’s revenue was up 82.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.63) earnings per share. Equities analysts expect that PROCEPT BioRobotics Co. will post -1.98 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in shares of PROCEPT BioRobotics by 5.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 128,732 shares of the company’s stock valued at $4,224,000 after purchasing an additional 7,035 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of PROCEPT BioRobotics by 23.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,721 shares of the company’s stock valued at $286,000 after acquiring an additional 1,684 shares during the period. TD Asset Management Inc increased its stake in shares of PROCEPT BioRobotics by 70.9% in the 3rd quarter. TD Asset Management Inc now owns 259,816 shares of the company’s stock valued at $8,525,000 after purchasing an additional 107,797 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in PROCEPT BioRobotics by 48.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 923,437 shares of the company’s stock worth $30,298,000 after purchasing an additional 303,003 shares during the period. Finally, M&T Bank Corp purchased a new position in PROCEPT BioRobotics during the third quarter worth approximately $293,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on PRCT. Wells Fargo & Company boosted their price objective on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Truist Financial increased their price target on PROCEPT BioRobotics from $63.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $49.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).